CytomX Therapeutics
CTMX
74 hedge funds and large institutions have $61.9M invested in CytomX Therapeutics in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 27 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 24
0.74% less ownership
Funds ownership: 65.79% → 65.05% (-0.74%)
16% less funds holding
Funds holding: 88 → 74 (-14)
30% less call options, than puts
Call options by funds: $30K | Put options by funds: $43K
36% less capital invested
Capital invested by funds: $97.1M → $61.9M (-$35.3M)
52% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$12.5M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.67M |
| 3 |
RI
RTW Investments
New York
|
+$2.39M |
| 4 |
Millennium Management
New York
|
+$2.34M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$7.73M |
| 2 |
SCM
Sio Capital Management
New York
|
-$3.48M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$2.72M |
| 4 |
BCM
Bronte Capital Management
Bondi Junction,
Australia
|
-$1.98M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.81M |
CTMX Hedge Fund Activity: Q2 2024 in Review
74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2024, worth a combined $61.9M — down 36% from $97.1M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CTMX and 13 opened new positions — a net loss of 14 holders — while 24 trimmed existing stakes and 29 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $12.5M. The largest seller was OrbiMed, exiting entirely with an estimated $7.73M sold.
- 74 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2024, down from 88 in Q1 2024.
- Funds reported $61.9M of CytomX Therapeutics stock for Q2 2024, down 36% quarter-over-quarter.
- 13 funds opened new CytomX Therapeutics positions in Q2 2024 and 27 closed out, a net change of -14 holders.
- The largest CytomX Therapeutics buyer in Q2 2024 was Janus Henderson Group, an estimated $12.5M added.
- The largest CytomX Therapeutics seller in Q2 2024 was OrbiMed, an estimated $7.73M sold.
Based on aggregated 13F filings for Q2 2024.